About Biocytogen
Biocytogen is a company based in Wakefield (United States) founded in 2008 by Yuelei Shen. Biocytogen has raised $301.11 million across 7 funding rounds from investors including NIH, Orbimed and SDIC. The company has 85 employees as of December 31, 2022. Biocytogen operates in a competitive market with competitors including Interius Biotherapeutics, Applied StemCell, GenOway, Nagi Bioscience and GemPharmatech, among others.
- Headquarter Wakefield, United States
- Employees 85 as on 31 Dec, 2022
- Founders Yuelei Shen
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Biocytogen Pharmaceuticals Beijing
-
Annual Revenue
$136.83 M (USD)38.7as on Dec 31, 2024
-
Net Profit
$4.68 M (USD)0as on Dec 31, 2024
-
EBITDA
$41.23 M (USD)0as on Dec 31, 2024
-
Total Equity Funding
$301.11 M (USD)
in 7 rounds
-
Latest Funding Round
$10 M (USD), Series D
Jun 22, 2021
-
Investors
NIH
& 11 more
-
Employee Count
85
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Biocytogen
Biocytogen is a publicly listed company on the SSE with ticker symbol 688796 in China, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Biocytogen
Unlock access to complete
Funding Insights of Biocytogen
Biocytogen has successfully raised a total of $301.11M across 7 strategic funding rounds. The most recent funding activity was a Series D round of $10 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Biocytogen
Biocytogen has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, Orbimed and SDIC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields.
|
Locked | Locked | Locked | |
|
Venture capital investments are managed for innovative company growth.
|
Locked | Locked | Locked |
Investor details for Biocytogen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Biocytogen
Investment portfolio details for Biocytogen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Biocytogen
Detailed financials for Biocytogen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Biocytogen Comparisons
Peer comparison for Biocytogen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Biocytogen
Biocytogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Interius Biotherapeutics, Applied StemCell, GenOway, Nagi Bioscience and GemPharmatech, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapies for treating multiple diseases
|
|
| Locked | Locked | Locked |
Provider of animal and cell line models as tools for drug discovery and diagnostics
|
|
| Locked | Locked | Locked |
Provider of transgenic rodent models and customized cell lines for preclinical development
|
|
| Locked | Locked | Locked |
Developer of a organism on a chip based technology
|
|
| Locked | Locked | Locked |
Humanized models and drug screening technologies are developed for research.
|
Detailed competitors of Biocytogen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Biocytogen
Complete news archive for Biocytogen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Biocytogen
Biocytogen was founded in 2008 and raised its 1st funding round 5 years after it was founded.
Biocytogen is headquartered in Wakefield, United States.
Yuelei Shen is the current CEO of Biocytogen. They have also founded this company.
Biocytogen is a funded company, having raised a total of $301.11M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Biocytogen is 85.
Annual revenue of Biocytogen is $136.83M as on Dec 31, 2024.
Biocytogen was founded in 2008 and is headquartered in Wakefield, United States. An integrated platform for antibody drug discovery and validation is offered within the biotechnology sector. Animal models are generated, therapeutic antibodies are discovered using RenMab mice, and preclinical studies are conducted in vivo or in vitro. These services support antibody-based therapeutic development for pharmaceutical applications.
Biocytogen's top competitors include Applied StemCell, GenOway and Champion Oncology.
Yes, Biocytogen is publicly traded on SSE under the ticker symbol 688796.
Biocytogen has 12 investors. Key investors include NIH, Orbimed, SDIC, Lake Bleu Capital, and Octagon Capital.
The ticker symbol of Biocytogen is 688796 on SSE.